How The Coronavirus Could Bolster Innovation Arguments Against US Price Controls

The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.

No strings attached
Trump Administration Will Not Dictate Prices Despite Concerns From House Democrats

US Health and Human Services Department secretary Alex Azar prioritized support for biopharma innovation over price controls during recent congressional hearings addressing the Trump administration’s response to the coronavirus outbreak.

His comments and those by House Republicans during the hearings highlighted the public health risk of discouraging industry investment into...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access